12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Daclatasvir: Additional Phase II data

Data from 16 treatment-naïve, non-cirrhotic patients with HCV genotype 1 infection in Part 1 of an open-label, international Phase II trial showed that an oral regimen of asunaprevir, daclatasvir and BMS-791325 for 24 weeks produced an SVR defined as undetectable HCV RNA levels (<25 IU/mL) 12 weeks after end of treatment in 94% of patients. Bristol-Myers said 1 patient withdrew consent. The SVR24 rate was 88%, with no virologic breakthroughs or relapses. In 16 patients who received asunaprevir, daclatasvir and BMS-791325 for...

Read the full 400 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >